Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M

Celldex Therapeutics, Inc.

2026-Q1 EPS reported -$1.18 revenue$15,000

Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.
Raised $345M gross in April 2026 public offering; cash at March 31, 2026 was $451.5M, supplemented by ~$323.9M net proceeds.
Q1 2026 net loss $78.7M ($1.18/share) vs $53.8M ($0.81) in Q1 2025; R&D expenses $73M, up from $52.6M.
Phase 1 CDX-622 proof-of-mechanism study in asthma ongoing; Phase 2 PN data summer 2026, AD data late 2026.
Revenue $0 in Q1 2026 (vs $0.7M); management expects cash to fund operations through 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2026.

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.